Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT03395522

Study to Assess the Efficacy of the iTind in Subjects With Symptomatic BPH

Conditions: BPH

Sex: Male
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 149
Sponsor: Medi-Tate Ltd.

Location: Sydney Adventist Hospital Clinical School of the University of Sydney Sydney

Summary

A total of up to 200 Symptomatic BPH subjects subjects will be enrolled into the study. Study duration will be 12 months post implantation with a follow-up visits at Year 2 and Year 3.

Eligibility Criteria

Inclusion Criteria: Subject signed informed consent prior to the performance of any study procedures. * Male with symptomatic BPH: IPSS symptom severity score ≥ 10 * Peak urinary flow of \< 12 ml/sec at flowmetry with minimum voided volume of at least 120 cc. * Prostate volume 25 ml to 80 ml (as assessed by TRUS) * Subject that is able to complete the study protocol * Normal Urinalysis and urine culture. Exclusion Criteria: * Previous prostate surgery * Prostate cancer * Urethral stricture * Bladder stones * An active urinary tract infection. * Obstructing median lobe demonstrated by IPP grade 3 (\>1 cm) as assessed by TRUS. * Neurological conditions potentially affecting voiding function. * A post void residual (PVR) volume \> 250 ml measured by ultrasound * Previous diagnosis or treatment for Over Active Bladder * Acute Urinary Retention * Any anatomical or physiological condition that in the opinion of the investigator likely to impede successful completion of the study Intra-Operation Exclusion: • Obstructing median lobe or any other anatomical or physiological pathology that can interfere the device implantation as assessed by cystoscopy.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT03395522). StuddyBuddy aggregates publicly available trial information.